IL-SEVAN
27.10.2021 15:02:16 CEST | Business Wire | Press release
Sevan Multi-Site Solutions, Inc. (Sevan) has positively impacted millions of lives worldwide through the implementation of customized, end-to-end turnkey solutions for 28,000 retail healthcare client sites.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005377/en/
Sevan — a global leader in innovative design, program management, construction services and data analytics — extends services to pharmacies, COVID testing centers, hospitals, wellness clinics, kidney dialysis centers, veterinary clinics, tele-med centers and dental facilities for varying clients ranging from small businesses to Fortune 100 companies.
“It is an honor to prioritize the healthcare needs of our population and deliver world class solutions for our clients that impact and simplify life for us all daily,” said Jim Evans, Sevan’s CEO and President. “The definition of healthcare is evolving, and many around the globe are doing everything we can to strengthen offerings for people’s growing needs. Hats off to all who are amplifying retail healthcare spaces—it’s a privilege to celebrate this milestone with our great clients, team, partners and everyone involved.”
Sevan’s customized, end-to-end turnkey solutions for some of the largest retail and restaurant brands across the United States, Canada and the United Kingdom have totaled more than 35 million square feet in client site touches.
Sevan offers multi-site solutions for clients along entire project life cycles including Technology & Data Analytics, Real Estate & Development Services, Civil Zoning & Permitting, Surveys & Facility Assessments, Architecture & Engineering, Construction Services and Program Management.
“It has been an immense pleasure to collaborate with our healthcare clients as they push forward with serving our nation’s immediate and long-term health needs,” said Jim Furis, Sevan’s Chief Revenue Officer. “Their combined passion, initiative and creativity in pursuing new business models, delivering healthcare to underserved markets or making it easier to fill a prescription impacts the lives of millions. We are proud to be part of transforming their locations to help so many do fantastic work!”
In 2021, Sevan was recognized as an Employee-Rated Great Place to Work® for the eighth consecutive year and ranked on the Inc. 5000 list of the nation’s fastest-growing private companies for the fourth consecutive year. Also in 2021, Sevan ranked No. 21 on Engineering News-Record (ENR)’s Top 50 Program Management Firms and No. 44 on ENR’s Top 100 Construction Management-for-Fee Firms. In 2020, Sevan ranked No. 124 on the Financial Times FT 1000 list of America’s Fastest-Growing Companies. Visit our website to learn more about Sevan, our 2021 award rankings and acquisitions .
About Sevan
Sevan helps iconic, global brands optimize their multi-site construction and facility programs in the U.S. and internationally. Sevan is headquartered near Chicago in Downers Grove, Illinois, with 400+ employees and has an international office in London.
The vision of Sevan Multi-Site Solutions is to be the best in the world at delivering innovative design, program management, construction services and data analytics to organizations with multiple sites. Sevan has a passion for sustaining people, the environment and its clients’ businesses. Sevan helps iconic global brands, including 7-Eleven, AAFES, Albertsons, Amtrak, BP, Chipotle, Corvias, DaVita, HCA Healthcare, HEB, Jiffy Lube, Kroger, Luxottica, McDonald’s, Office Depot, QDOBA, Starbucks, Sunoco, Walgreens Boots Alliance, Walmart, WOW Carwash, Yum! Brands and Zaxby’s. Sevan rolls out multi-site initiatives efficiently, predictably and transparently. Applying breakthrough technology solutions, Sevan optimizes construction of new builds, rebuilds, remodels and renovations. Sevan has licensed architects in 49 states as well as D.C., Canadian provinces, Guam and the Northern Mariana Islands. Sevan has professional engineers on staff and general contractor licenses in more than 25 states. Since Sevan’s inception in 2011, the team has refreshed more than 21,000 retail stores and 14,000 restaurants. The team has also completed more than 28,000 surveys, totaling more than 700 million square feet. Sevan Elevate, a program that reinforces and continuously improves safety and sustainability across the company, is designed to impactfully deliver excellence to Sevan’s people and clients. To read more about Sevan, visit www.sevansolutions.com .
For more information, please contact Hafsa Mahmood by calling 312.285.0590 or via email at hafsa.mahmood@sevansolutions.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005377/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom